DELRAY BEACH, Fla., Oct. 5, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the AI in Protein Engineering Market is projected to reach USD 3.82 billion by 2031 from USD 1.44 billion in 2026, at a CAGR of 21.6% during the forecast period.

Browse 350 market data Tables and 50 Figures spread through 450 Pages and in-depth TOC on "AI in Protein Engineering Market - Global Forecast to 2031"

AI in Protein Engineering Market Size & Forecast:

- Market Size Available for Years: 2026–2031

- 2026 Market Size: USD 1.44 billion

- 2031 Projected Market Size: USD 3.82 billion

- CAGR (2026–2031): 21.6%

AI in Protein Engineering Market Trends & Insights:

- North America dominates the AI in protein engineering market, with a share of 48.6% in 2025.

- By offering, software/platforms dominate the market with a share of 75.4% in 2025.

- By protein type, the miniproteins segment is expected to register the highest CAGR of 23.7% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=27766714

Market expansion of AI in protein engineering is being propelled by the increasing complexity of protein discovery and optimization, growing AI investment, and the need for faster, more cost-efficient R&D. AI technologies, including machine learning and deep learning, protein language models, generative AI, and structure-based AI, are increasingly applied to protein discovery, de novo design, sequence optimization, structure prediction, and developability assessment. According to a 2025 Benchling survey of ~100 biotech and pharmaceutical organizations, 55% allocated at least 11% of their R&D technology budgets to AI, including 28% allocating 11–20%, 18% allocating 21–35%, and 6% allocating >35%. AI adoption is also expanding, with 48% reporting strategic AI integration and 87% reporting AI agents embedded in workflows, products, or services. AI is also demonstrating productivity gains, with Recursion reporting approximately 330 compounds per program over 17 months, compared with an industry average of 2,500+ compounds over 42 months. Moreover, 88% planned to increase cloud/infrastructure investment, 86% data-platform investment, and 84% AI-platform investment. However, adoption remains constrained by scaling, data, talent, computational, and validation challenges, with only 22% successfully scaling AI and 9% achieving significant returns. These trends are expected to accelerate adoption of AI-powered protein engineering platforms while organizations seek to reduce experimental iterations and improve R&D productivity.

By application, the next-generation biologics segment is expected to register the fastest growth rate during the forecast period.

By application, next-generation biologics is expected to be the fastest-growing segment of the AI in protein engineering market. This segment's growth is driven by increasing demand for novel, more effective protein therapeutics; the rising complexity of biologic molecules; and growing adoption of AI for de novo protein design, antibody discovery and optimization, enzyme engineering, and protein stability and developability optimization. Pharmaceutical and biotechnology companies are increasingly leveraging AI-powered protein engineering platforms to explore large protein sequence spaces, identify promising candidates, and accelerate the design–build–test cycle. Additionally, advances in protein language models and generative AI are enabling the design of novel proteins with desired structural and functional properties, further supporting adoption in next-generation biologics. As investment in innovative biologic modalities continues to increase, demand for AI-enabled protein design and optimization solutions is expected to accelerate, helping organizations reduce experimental iterations, improve candidate selection, and shorten development timelines.

By AI tool, generative AI accounted for the largest share of the AI in protein engineering market in 2025.

By AI tool, generative AI accounted for the largest share of the AI in protein engineering market in 2025. This dominance can be attributed to the growing adoption of generative AI for de novo protein design, antibody generation and optimization, enzyme engineering, and protein sequence generation. Generative AI models enable researchers to explore vast protein sequence spaces and design novel proteins with desired structural and functional properties, reducing reliance on conventional trial-and-error approaches. Furthermore, the growing availability of large-scale protein datasets, advances in foundation models and generative architectures, and integration with high-throughput experimental workflows are improving the scalability and efficiency of AI-driven protein engineering. The growing use of generative AI by pharmaceutical and biotechnology companies to accelerate protein discovery and optimize therapeutic candidates is expected to further strengthen its market leadership.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=27766714

The Asia Pacific is expected to be the fastest-growing market during the forecast period.

The AI in protein engineering market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Asia Pacific is projected to be the fastest-growing regional market for AI in protein engineering, driven by increasing investments in biotechnology and pharmaceutical R&D, expanding AI and computational biology capabilities, and growing adoption of AI-enabled approaches for protein discovery, design, and optimization. Countries such as China, India, Japan, South Korea, and Australia are strengthening their life sciences and AI ecosystems through government-backed research programs, expanding biopharmaceutical manufacturing, and investments in advanced computing and biotechnology infrastructure. China invested about RMB 3.63 trillion (USD ~500 billion) in R&D in 2024, an 8.9% year-over-year increase, with basic research spending up 10.7%, supporting the development of advanced computational and life sciences capabilities. India's bioeconomy reached USD 165.7 billion in 2024, more than 16-fold higher than in 2014, while the government continues to promote biotechnology innovation through initiatives such as BioE3 and increased support for biotech startups. Japan also recorded JPY 22.05 trillion in total R&D expenditure in FY2023, with pharmaceutical R&D expenditure reaching JPY 1.54 trillion, up 7.6%, highlighting the region's strong pharmaceutical research base. These investments are creating favorable conditions for adopting protein language models, generative AI, structure-based AI, machine learning, and deep learning for applications including de novo protein design, antibody discovery and optimization, enzyme engineering, and protein stability prediction. Furthermore, the growing presence of pharmaceutical companies, biotech startups, CROs, academic research institutes, and AI-protein engineering companies across the region is expected to accelerate the deployment of AI-enabled protein engineering platforms and strengthen Asia Pacific's position as the fastest-growing regional market.

Key Players

Leading players in the AI in Protein Engineering companies include Schrödinger, Inc. (US), XtalPi (China), Dassault Systèmes (France), NVIDIA Corporation (US), Generate: Biomedicines (US), Absci Corp. (US), Insilico Medicine (US), Isomorphic Labs (UK), among others.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=27766714

AI in Protein Engineering Market - Investment & funding +Merger & Acquisition

Investment Funding Context

The AI in protein engineering market is witnessing increasing investment activity, supported by growing investor and pharmaceutical interest in generative AI, protein foundation models, and de novo protein design. In 2024, EvolutionaryScale raised USD 142 million to develop AI models that generate novel proteins, while in February 2025, Latent Labs secured USD 50 million to advance generative AI models for protein design. Investment momentum continued in November 2025, when AI Proteins raised USD 41.5 million in Series A financing to advance AI-designed de novo miniprotein therapeutics. The funding environment is further supported by growing pharmaceutical-industry collaboration, with 120 AI-based target and drug discovery deals recorded in 2025, representing 23% of the 513 such deals tracked since 2017; total potential deal value reached USD 29.7 billion, with nearly USD 800 million committed upfront. These investments and strategic collaborations highlight increasing confidence in AI-enabled protein design and are expected to support the development of generative protein design, antibody engineering, enzyme optimization, and next-generation biologics.

Revenue Shift Context

The market is shifting toward AI-driven, computationally enabled platforms that accelerate protein discovery, design, and optimization. The AI in protein engineering market is projected to rise from USD 1.44 billion in 2026 to USD 3.82 billion by 2031, at a CAGR of 21.6%, with much of this growth concentrated in AI-powered protein design, generative protein engineering, protein language models, antibody discovery and optimization, enzyme engineering, and protein stability and developability solutions. Meanwhile, software/platforms accounted for 75.4% of the market in 2025, highlighting strong adoption of AI-enabled platforms, while emerging areas such as generative AI, de novo protein design, protein language models, and AI-driven optimization are capturing a rising share of new spending.

Mergers and Acquisitions

Mergers and acquisitions in the AI in protein engineering market are gaining momentum, with companies increasingly targeting AI-driven protein design, computational biology, and generative AI capabilities.

The SERD market is expected to grow significantly due to factors like improved diagnosis, treatment advancements, demographics, increased awareness, and supportive regulations in the 7MM. Additionally, the recent approvals of SERD drugs such as AstraZeneca's ETCAMAH (camizestrant) and pipeline activity of emerging therapies including Palazestrant (Olema Pharmaceuticals), Giredestrant (Roche), Borestrant (EnhancedBio/Zenopharm), D-0502 (Inventis Bio), and others are expected to fuel the market of SERD by 2036.

LAS VEGAS, Oct. 5, 2026 /PRNewswire/ -- DelveInsight's SERD Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as ER+/HER2- breast cancer, Endometrial cancer, HER2+ breast cancer, Ovarian cancer, ESR1 mutated breast cancer, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging SERD drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets (the US, EU4, UK, and Japan).

Key Takeaways from the SERD Market Report

- The total SERD market size is expected to grow positively by 2036 in the leading markets.

- The United States accounted for the largest SERD market size of the total market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

- The report provides the total potential number of patients in the indications, such as ER+/HER2- breast cancer, Endometrial cancer, HER2+ breast cancer, Ovarian cancer, ESR1 mutated breast cancer, and others.

- HR+/HER2- breast cancer is one of the leading target indication for use of SERDs in the 7MM with total cases of nearly 485,000 in 2025, which is expected to increase by 2036 in the 7MM.

- Leading SERD companies, such as Olema Pharmaceuticals, Roche, EnhancedBio, Zenopharm, Inventis Bio, Atossa Therapeutics, Hengrui Medicine, Simcere, Kind Pharmaceuticals, and others, are developing novel SERD drugs that can be available in the SERD market in the coming years.

- Some of the key SERD drugs in clinical trials include Palazestrant, Giredestrant, Borestrant, D-0502, (Z)-Endoxifen, HRS-8080, SIM0270, AND019, and others.

Discover what patient populations may benefit most from treatment with oral SERDs @ https://www.delveinsight.com/report-store/serd-market-forecast

Key Factors Driving the SERD Market

- Rising Prevalence of Hormone Receptor-Positive Breast Cancer: The growing incidence of estrogen receptor-positive (ER+) breast cancer is increasing the demand for effective endocrine therapies. SERDs directly target estrogen receptor signaling, creating a strong addressable patient population.

- Increasing Resistance to Existing Endocrine Therapies: Acquired resistance to aromatase inhibitors and selective estrogen receptor modulators remains a major treatment challenge. SERDs offer a differentiated approach by binding to and promoting degradation of the estrogen receptor, potentially addressing resistance mechanisms.

- Growing Adoption of Oral SERDs: The development of oral SERDs is improving treatment convenience compared with injectable or intramuscular endocrine therapies. The recent approval of AstraZeneca's ETCAMAH (camizestrant) is further strengthening the shift toward oral SERDs in hormone receptor-positive, HER2-negative advanced breast cancer.

- Expansion of SERDs Into Earlier Lines of Therapy: Clinical development is increasingly evaluating SERDs in earlier treatment settings and in combination with other targeted therapies. Successful results could expand their use beyond heavily pretreated or advanced disease.

- Combination With Targeted Cancer Therapies: SERDs are being investigated alongside CDK4/6, PI3K, AKT, and other targeted inhibitors to improve treatment outcomes. These combination strategies are broadening the potential role of SERDs within precision oncology.

- Launch of Emerging SERD Drugs: The dynamics of the SERD market are expected to change in the coming years due to the launch of emerging therapies such as Palazestrant (Olema Pharmaceuticals), Giredestrant (Roche), Borestrant (EnhancedBio/Zenopharm), D-0502 (Inventis Bio), (Z)-Endoxifen (Atossa Therapeutics), HRS-8080 (Hengrui Medicine), SIM0270 (Simcere), AND019 (Kind Pharmaceuticals), and others.

Sadaf Javed, Functional Head of Forecasting & Analytics at DelveInsight, said that the SERD market is indeed growing, with camizestrant and imlunestrant leading the way. This creates a significant opportunity for other players like Roche, which is developing giredestrant, an upcoming SERD.

SERD Market Analysis

- Elacestrant became the first oral SERD to receive regulatory approval in the modern SERD era, introducing a new treatment option for patients with ESR1-mutated, ER+/HER2− advanced or metastatic breast cancer (mBC) following endocrine therapy.

- The therapeutic class is now entering a more competitive phase with the recent approvals of imlunestrant and AstraZeneca's camizestrant, further expanding the SERD treatment landscape and its commercial potential.

- The SERD landscape is shifting from injectable fulvestrant toward oral, next-generation estrogen receptor degraders, reflecting the need for more convenient endocrine treatment options and improved management of endocrine-resistant ER+/HER2− breast cancer.

- Recent market growth has been driven by elacestrant and imlunestrant, both of which are positioned for ESR1-mutated advanced or metastatic disease.

- A major challenge for SERDs remains the ability to demonstrate meaningful clinical benefits over established endocrine therapy and CDK4/6 inhibitor regimens, particularly in earlier lines of treatment.

- Biomarker-based patient selection will therefore be critical, with the identification of emergent ESR1 mutations expected to play an important role in optimizing treatment efficacy and supporting broader adoption of SERDs.

- Despite recent regulatory advances, the SERD class continues to face substantial late-stage development risk.

- Amcenestrant and giredestrant failed to meet their primary endpoints in Phase III trials, while camizestrant did not demonstrate a statistically significant improvement in PFS in SERENA-4.

- These outcomes underscore the difficulty of establishing superiority over established endocrine therapy/CDK4/6 inhibitor combinations.

- The emerging SERD pipeline includes several notable candidates, including giredestrant from Roche, palazestrant from Olema Pharmaceuticals, borestrant from EnhancedBio/Zenopharm, and D-0502 from Inventis Bio, among others.

Learn more about best SERD for ER-positive metastatic breast cancer @ Oral SERD Breast Cancer

SERD Competitive Landscape

Some of the SERD drugs under development include Palazestrant (Olema Pharmaceuticals), Giredestrant (Roche), Borestrant (EnhancedBio/Zenopharm), D-0502 (Inventis Bio), (Z)-Endoxifen (Atossa Therapeutics), HRS-8080 (Hengrui Medicine), SIM0270 (Simcere), AND019 (Kind Pharmaceuticals), and others.

Roche's Giredestrant is an investigational selective estrogen receptor degrader (SERD) designed to completely inhibit estrogen receptor signaling while achieving robust receptor occupancy. Estrogen promotes the proliferation of hormone receptor-positive breast cancer cells by binding to estrogen receptors. Giredestrant is currently being investigated across multiple settings, including first-line (1L) ER+/HER2– metastatic breast cancer, 1L ER-positive/HER2-positive breast cancer, 1L endocrine therapy-resistant ER+/HER2– breast cancer, adjuvant ER+ breast cancer, endometrial cancer, and ovarian cancer.

Olema Pharmaceuticals' Palazestrant (OP-1250) is a novel, orally administered small molecule that combines complete estrogen receptor antagonist (CERAN) and SERD activities. It is currently being evaluated in patients with recurrent, locally advanced, or metastatic ER+/HER2– breast cancer. The U.S. FDA has granted Fast Track designation (FTD) to palazestrant for the treatment of ER+/HER2– metastatic breast cancer. The therapy is being assessed as a monotherapy in the ongoing pivotal Phase III OPERA-01 trial and in combination with ribociclib in the pivotal Phase III OPERA-02 trial.

EnhancedBio/Zenopharm's Borestrant is a first-in-class, small-molecule, steroidal oral SERD under clinical development for patients with ER+/HER2– locally advanced or metastatic breast cancer. It is currently being evaluated in a Phase I/II clinical trial in patients with ER+/HER2– locally advanced or metastatic breast cancer.

The anticipated launch of these emerging therapies are poised to transform the SERD market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the SERD market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about oral SERD, visit @ Oral SERD Drugs

Recent Developments in the SERD Market

- In September 2026, AstraZeneca's camizestrant in combination with CDK 4/6 inhibitor had been approved in the US for the treatment of adult patients with HR+, HER2–, locally advanced or metastatic breast cancer upon detection of ESR1 mutation and without disease progression during 1L endocrine therapy

- In June 2026, Roche announced that the US FDA had accepted the company's NDA under Priority Review for giredestrant as an adjuvant treatment for adults with ER+/HER2–, stage I, II, and III breast cancer.

PITTSBURGH, Oct. 5, 2026 /PRNewswire/ -- "I wanted to create a convenient caddy that would assist in maintaining a proper skin care routine," said an inventor, from South Attleboro, Mass., "so I invented the DERMOVA. My design ensures there is specific place for all your skin care products and instructions for how/when to use them."

The invention provides a new caddy/organizer for face and skin care. In doing so, it ensures the user follows a proper skin care routine. As a result, it increases convenience. It also could help solve skin care issues faster and more effectively. The invention features a durable design that is easy to use so it is ideal for the general population.

The original design was submitted to the Boston sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 25-BKC-965, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at http://www.InventHelp.com.

SOURCE InventHelp

Share this article

Recognizing 26 Businesses Championing Local Wine Across the Commonwealth

RICHMOND, Va., Oct. 5, 2026 /PRNewswire/ -- Virginia Wine extends well beyond the vineyard. The Stewards of Virginia Wine Awards recognize restaurants, wine bars, retailers and other businesses that actively support Virginia Wine through their wine selections, educational efforts, events and promotions.

Now in its second year, the program received twice as many nominations as its inaugural year, with 26 businesses recognized for sharing and promoting Virginia Wine. The honorees once again include businesses outside Virginia, reflecting support for the state's wines beyond its borders.

Through wine lists that reflect Virginia's diversity, by-the-glass offerings, staff education, and creative programming, these businesses introduce more people to wines grown and made in Virginia.

2026 Stewards of Virginia Wine Recipients

*Judges' Award – Honoring the top five nominees who achieved the highest scores for excellence in promoting Virginia Wine.

"The response to this year's program shows how deeply restaurants, retailers, and hospitality leaders believe in Virginia wines, both throughout the Commonwealth and beyond state lines" said Desiree Harrison-Brown of the Virginia Wine Board Marketing Office. "These Stewards are some of the most important voices for Virginia Wine. They introduce guests to producers and regions and keep local stories front and center. We are grateful for their commitment and excited to celebrate with them."

The Selection Process

The Stewards of Virginia Wine Awards welcomed nominations from wineries, distributors, consumers and trade partners. Eligible nominees completed an application detailing their support and promotion of Virginia Wines, which was reviewed by an industry panel using a standardized rubric. Applications were evaluated across five areas: wine list presence, consumer promotion, creativity, staff education and overall commitment to Virginia Wine.

An optional bonus point recognized exceptional community impact or advocacy. Honorees were selected for the ways they champion Virginia Wines and help strengthen their presence across hospitality and retail.

About the Stewards of Virginia Wine Awards

The Stewards of Virginia Wine Awards honor restaurants, wine bars, and retailers that demonstrate exceptional dedication to Virginia-grown wines. The program celebrates the creativity, leadership, and community spirit that help strengthen Virginia's place among the country's leading wine regions.

About Virginia Wine

Home to more than 300 wineries, Virginia is one of the most dynamic and fastest-growing wine regions in the country. The Virginia Wine Board Marketing Office promotes the development, growth, and awareness of Virginia's wine industry through education, marketing, and collaborative programs that highlight the quality and diversity of Virginia Wines.

SOURCE Virginia Wine

Share this article

ROCHESTER HILLS, Mich., Oct. 5, 2026 /PRNewswire/ -- FANUC America, a global industrial automation leader, will feature advanced automation technologies for the fabrication industry at FABTECH 2026, including advanced welding automation, collaborative robotics, laser processing and paint automation.

- In FANUC's Main Booth #S40006, attendees can experience a variety of robotic welding, plasma cutting and laser processing solutions, from easy-to-program collaborative welding applications to advanced fabrication technologies.

- In FANUC's Paint Booth #S11008, attendees will see advanced robotic painting demonstrations, including collaborative and industrial paint robots designed to improve coating quality, consistency and operational flexibility.

Highlights include the FABTECH debut of FANUC's CRX-3iA collaborative robot and P-55/15-21A paint robot, as well as demonstrations showcasing a coordinated-motion welding application featuring a CRX-10iA/L cobot on an integrated seventh-axis rail and an LR-10iA/10 laser processing cell that combines automated laser welding and marking within a single work cell.

"At FABTECH 2026, FANUC is demonstrating how automation is expanding into applications that were once difficult to automate, from vertical-up welding on large structural steel components to collaborative welding systems that simplify deployment and operation," said Eric Potter, FANUC America Vice President, Product Management and Application Engineering, Robot and ROBODRILL. "These technologies help fabricators improve productivity and quality while bringing automation to a broader range of welding and cutting applications."

Innovations in Welding Automation

FANUC's CRX collaborative robots and industrial robots help manufacturers automate welding operations while maintaining the flexibility, precision and ease of use required in today's fabrication environments. At FABTECH, attendees will find a variety of robotic welding demonstrations, including:

- Automated Portable Welding: The lightweight (11 kg) and portable CRX-3iA collaborative robot can manage 3 kg payloads and be mounted directly to structural steel using a magnetic base, bringing robotic vertical-up welding to applications such as shipbuilding and large structural fabrication where automation has traditionally been difficult to use.

- Easy Programming: An intuitive FANUC interface featuring wrist-mounted controls and Servo Robot Smart Ring technology with a path-planning algorithm that allows operators to create weld programs quickly and accurately through a scan, as demonstrated from this CRX-10iA/L collaborative robot.

- Collaborative Arc Welding with Aux Axes: The FANUC CRX-10iA/L collaborative robot moves along a seventh-axis linear track and a positioner rotates a lawn mower deck 180 degrees to perform seam-track welds on multiple sides.

- One Cell, Multiple Operations: FANUC CRX-30iA and CRX-10iA collaborative robots automate assembly, welding and post-process weld inspection in a single work cell, illustrating how manufacturers can combine multiple fabrication steps into one streamlined operation.

- Built for Bigger Welds: Featuring a 500 kg payload and 2,830 mm reach, the FANUC M-950/500F-28A works alongside two ARC Mate robots to simulate excavator bucket welding for heavy equipment and construction applications.

Advanced Fabrication Technologies

FANUC will demonstrate robotic technologies that help manufacturers automate cutting and welding processes while improving consistency and production efficiency.

- Simplified Plasma Cutting: Shape Generation 3 software and a dedicated Hypertherm plasma cutting equipment interface simplify programming and setup for robotic plasma cutting in a CRX-10iA/L demonstration, helping manufacturers bring automated cutting operations online faster without requiring extensive programming expertise.

- Laser Welding and Marking Automation: FANUC's LR-10iA/10 laser processing cell demonstrates automated laser welding and marking sheet metals. The robot performs precision corner welding of stainless steel before laser marking each finished part, showing how manufacturers can combine multiple value-added processes within a single automated work cell.

- Automated Torque Tightening: Featuring a CRX-30iA collaborative robot with a 30 kg payload, this demonstration tightens bolts on a dozer track using integrated force control and screw-tightening technology. Real-time torque validation and process feedback help manufacturers improve fastening accuracy, verify quality and support critical assembly operations.

AI-Powered Automation:

FANUC will demonstrate an AI-enabled automation solution that combines Google Cloud, Gemini Enterprise, machine vision and robots to simplify material handling and production support tasks.

- AI-Powered Kitting: This demonstration shows how a Gemini Enterprise AI agent can interpret handwritten work orders, determine required parts and quantities, and generate picking instructions for automated kitting tasks. A CRX-20iA collaborative robot equipped with FANUC iRVision technology captures handwritten instructions, which are sent to the Google Cloud computing platform for interpretation by the AI Agent to determine the required parts and quantities. An LR Mate then picks and places the components based on those instructions, helping manufacturers simplify automation adoption while streamlining material preparation for fabrication and assembly operations.

New Automated Robotic Painting Solutions

FANUC's paint automation technologies help manufacturers improve coating quality, consistency and process control while increasing production flexibility.

- Advanced Paint Automation with Line Tracking: The new P-55/15-21A paint robot uses integrated line tracking and its 2,100 mm reach with a VersaBell 3 applicator to paint moving football helmets, demonstrating how manufacturers can maintain consistent coating quality even when parts are continuously in motion.

- Flexible Finishing for Any Operation: As the world's first explosion-proof collaborative paint robot, FANUC's CRX-10iA/L Paint model, featuring a 10 kg payload and 1,418 mm reach, uses Scan-to-Path and No Code programming capabilities to simplify automation for high-mix finishing applications that require frequent product changeovers.

Advanced Automation Technologies

Across its exhibits, FANUC will showcase advanced automation technologies including FANUC iRVision®, coordinated motion, integrated force control, laser processing, collaborative robotics, Google Cloud, Gemini Enterprise and the latest R-50iA and R-30iB Plus controller platforms. Together, these technologies help manufacturers simplify programming, improve quality and increase flexibility across welding, fabrication, assembly and finishing operations.

About FANUC America Corporation

FANUC America Corporation is a subsidiary of FANUC CORPORATION in Japan and provides industry‑leading CNC systems, robotics, and ROBOMACHINEs. FANUC's innovative technologies help manufacturers maximize productivity, reliability, and profitability. Headquartered in Rochester Hills, Michigan, FANUC America has facilities throughout North and South America. Learn more at www.fanucamerica.com or explore collaborative robots at crx.fanucamerica.com.

Media Contact:

[email protected]

SOURCE Fanuc America Corporation

Share this article

New solution centralizes SDS access, improves document control, and features AI-assisted capabilities to help employees find critical safety information when they need it

WASHINGTON, Oct. 5, 2026 /PRNewswire/ -- CHEMTREC, a trusted leader in safety and compliance solutions for 55+ years, today announced the launch of its new SDS Management platform, designed with manufacturers in mind, to help organizations simplify the way they access, organize, maintain and share safety data sheets (SDSs).

Organizations shouldn't have to chase down SDSs. Yet for many teams, managing safety data sheets still means searching through scattered files, shared drives, spreadsheets and paper binders while navigating time-consuming administrative and compliance tasks. CHEMTREC's SDS Management platform offers a more modern approach, bringing together centralized SDS access, fast search, QR Code and mobile capabilities, employee self-service, AI-assisted tools and streamlined document distribution.

Users can also search CHEMTREC's Master SDS Library and link available documents directly to their company's library, helping reduce the time and effort spent sourcing and managing SDSs. The result is a smarter, more efficient way to manage SDSs while supporting Hazard Communication, compliance, and workplace safety programs.

"The gold standard for emergency response is rapid access to an accurate, current SDS," said Andrew LaVanway, Chief Executive of CHEMTREC. "The what is simple, but the how is where it gets hard. Our SDS Management platform helps organizations simplify the work of achieving that standard. One place, one link, one click."

CHEMTREC launched an SDS Management platform because we uniquely understand the importance of getting the right SDS into the hands of the right person when it matters most. Customers can manage SDS authoring, maintenance, access, and emergency response through one provider. CHEMTREC understands why SDS accuracy, accessibility, and distribution matter because our teams rely on SDS information every day to support safety and incident management.

For organizations managing SDS programs across multiple facilities, the platform can support multiple locations, helping businesses expand their SDS management program as their needs evolve.

"Early access from our existing customers has been an important part of bringing this platform to market," said Heather Walker, Director of Product Management and Development at CHEMTREC.

"Customers have told us that the platform offers a more intuitive experience and stronger capabilities than other SDS management solutions they've used. That feedback reinforces what we set out to accomplish: create a modern, competitive solution that makes SDS management easier while delivering the level of service and support customers expect from CHEMTREC," said Walker.

The launch further strengthens CHEMTREC's broader Safety Data Sheet Solutions. Organizations can pair the new SDS Management platform with CHEMTREC's SDS Authoring services, providing access to SDS creation, maintenance, and management through a single provider.

To learn more about CHEMTREC SDS Management or request a demo, visit https://www.chemtrec.com/sds-management.

About CHEMTREC

CHEMTREC is a global provider of emergency response information, regulatory support, and safety management solutions. Operating 24/7, CHEMTREC helps organizations navigate compliance and incident management challenges through a comprehensive suite of services, including emergency response, safety data sheet solutions, training, consulting, and lithium battery compliance support. With worldwide coverage and regional expertise, CHEMTREC delivers reliable services that help organizations protect people, the environment, and operations.

SOURCE CHEMTREC, LLC

Share this article

New insights from TruGrid show how connecting engineering, procurement, and construction before mobilization strengthens financing confidence for energy storage and solar projects.

HOUSTON, Oct. 5, 2026 /PRNewswire/ -- TruGrid, a leading energy storage and solar company that provides engineering, procurement, and construction (EPC) as well as operations and maintenance (O&M) services, has released new insights on how the right EPC partner can reduce risk before construction begins.

The article details three areas where TruGrid's EPC model can reduce risk:

- Design to Build: A buildable project starts with the right design and engineering partner. TruGrid shares how the engineer of record selection can help identify constructability issues early, reducing costly surprises during construction.

- Price Beyond the Price Tag: The lowest equipment price doesn't always mean the lowest project cost. TruGrid examines how lead times, tariffs, foreign entities of concern requirements, domestic content, supplier stability, and other factors can turn sourcing decisions into schedule and financing decisions.

- Plan for the Real World: Execution starts long before crews mobilize. TruGrid outlines how planning for safety, quality, labor, and subcontractor performance can create a more predictable path between construction and commissioning.

"No EPC can eliminate every risk from an energy project. What matters is how early you identify those risks and how many options you have," says TruGrid Chief Commercial Officer Chris Finley. "Our track record of completing projects on time and within budget, all while maintaining a 0.0 TRIR throughout 2025 and year to date in 2026, reflects our values and discipline. For developers and project investors, that execution history provides something that a project model can't: evidence of a team that can deliver bankable projects."

The article continues to outline that when engineering, procurement, and construction strategies are evaluated together, developers gain greater confidence in their design, clearer visibility into supply chain risk, more defensible cost and schedule assumptions, and a stronger story for lenders and investors.

To learn how an experienced EPC partner can help de-risk your next project, read the full blog or email [email protected].

About TruGrid

TruGrid is a premier utility-scale engineering, procurement, and construction (EPC) contractor specializing in battery energy storage systems (BESS) and solar technology. Its mission is to connect customers and communities with reliable and valuable utility-scale clean energy projects. Based in Houston, Texas, TruGrid is at the forefront of North America's energy transition, offering solutions that ensure the most profitable projects for customers. Proudly owned by Hull Street Energy, TruGrid is dedicated to advancing sustainability and leading the energy industry with a focus on excellence, safety, and reliability.

Amy Norstedt

Senior Director of Marketing

[email protected] 

SOURCE TruGrid

Share this article

CINCINNATI, Oct. 5, 2026 /PRNewswire/ -- EXAIR has unveiled a redesigned website that delivers a more streamlined experience for engineers, maintenance professionals, and manufacturers searching for compressed air solutions. Featuring a modern look that reflects EXAIR's updated brand identity, the new website makes it easier than ever to explore products, learn about applications, and find the right solution for virtually any industrial challenge. Built with performance and usability in mind, the site offers faster page loads, improved navigation, and a cleaner interface.

The redesigned website introduces several customer-focused enhancements that simplify the buying process from research to checkout. A streamlined shopping experience reduces the number of steps required to purchase products, allowing customers to move from product selection to checkout more quickly than ever before. Visitors can also browse new industry-specific pages featuring relevant product recommendations, application examples, and educational resources, making it easier for users to discover solutions designed specifically for their manufacturing environment. The site also offers ample opportunities to connect with EXAIR through catalog requests, newsletter signups, or speaking directly with Application Engineers to get answers for case-by-case manufacturing dilemmas.

EXAIR.com reinforces EXAIR's commitment to providing customers with the tools and resources needed to solve industrial challenges efficiently. In addition, visitors have access to the application database, videos, CAD models, blogs, an extensive Knowledge Base, and direct support from EXAIR's Application Engineers. Combined with enhanced site performance and an improved user experience, the redesigned website makes finding, selecting, and purchasing EXAIR solutions easier than ever. https://exair.co/91-newsite

SOURCE EXAIR

Share this article

AKEEYO to Showcase the 711Air Ultra-Light Ride Camera at Global Sources Hong Kong 2026

SHENZHEN, China, Oct. 5, 2026 /PRNewswire/ -- AKEEYO, a brand of dash cams and ride cameras for cars, motorcycles and bikes, will exhibit at the Global Sources Hong Kong Shows this October. At the show, AKEEYO will present its new 711Air alongside the AKY-710Lite, AKY-730Pro, NV-X2, XPRO and 750Lite for global buyers, distributors and media.

For AKEEYO, Global Sources Hong Kong is the right stage to introduce the 711Air. Buyers and brand owners can handle the 80g body and try one-touch recording in person, and dealers interested in partnering with AKEEYO are welcome to fill out the inquiry form at link.

Products on Display

New: 711Air, a lightweight dash cam for two-wheel riders, built for helmet wear, designed to be light, long-lasting and easy to use.

- Long battery life: an 1800mAh battery supports 8-10 hours of continuous recording.

- Ultra-light design: at only 80g, it is barely noticeable when worn with a helmet.

- One-touch recording: a single press starts recording, and motor (haptic) feedback confirms power on/off and recording status without looking at the device.

- AOV long-duration monitoring: supports up to 36 hours of monitoring.

- Connected and upgradeable: 2.4G Wi-Fi, companion app and OTA firmware updates.

Also on display

- AKY-730Pro: AKEEYO's flagship 4K touchscreen camera for motorcycles and bicycles.

- AKY-710Lite: a long-battery-life camera for riders who record on longer trips.

- 750Lite: the endurance specialist for long-haul touring and all-day delivery, recording up to 24 hours at 1080p and monitoring for up to 120 hours in AOV mode.

- NV-X2: a next-generation night vision dash cam with dual 2K lenses and large F1.0 front and F1.7 rear apertures, built to capture clear footage after dark.

- XPRO: built for select Toyota RAV4 models, replacing the original mirror housing with a factory-style 4K dash cam. Custom-fit solutions are also available for popular vehicle models across different markets.

Visit AKEEYO at Global Sources 2026

- Show: Global Sources Consumer Electronics & Global Sources Electronic Components

- Dates: October 11-14, 2026

- Venue: 1st Floor, AsiaWorld-Expo, Hong Kong

- AKEEYO Booth: 5D12

About AKEEYO

AKEEYO designs dash cams and ride cameras for cars, motorcycles and bicycles, built for real road conditions with 4K capture, weatherproof construction, and app-based control.

Website: www.akeeyo.com

Share this article

McClintock, who has served as Interim CEO since August 2026, appointed to lead Fusion Connect's next phase of growth

ATLANTA, Oct. 5, 2026 /PRNewswire/ -- Fusion Connect ("Fusion" or the "Company"), a leading provider of cloud communications and managed services, today announced that its Board of Directors has appointed Brian McClintock as Chief Executive Officer and a member of the Board of Directors, effective immediately. McClintock has served as Interim CEO since August 2026 and previously served as Fusion Connect's Chief Financial Officer for three years.

During his tenure as CFO and Interim CEO, McClintock has played a central role in Fusion Connect's operational transformation, financial performance and continued focus on delivering an exceptional customer experience. The company's strong customer service performance is reflected in a Net Promoter Score (NPS) of +50 and a customer satisfaction rating of 4.7 out of 5.0.

"Brian has proven himself to be an exceptional leader who has delivered strong operational, service and financial results," said Dudley Slater, Chairman of the Board of Directors at Fusion Connect. "He has helped guide the company through an important transformation while shaping a clear strategy for the future. The Board is unanimous in its belief that Brian is the right leader to build on this momentum and lead Fusion through its next phase of growth."

McClintock brings more than two decades of industry and executive leadership experience to the role, including senior financial and operational positions at Fusion Connect, Impact Telecom, KDDI Global and New Global Telecom. His experience spans finance, operations, strategy and organizational transformation across the communications and technology industries.

"I am honored to lead Fusion Connect at an important time for our company and our industry," said Brian McClintock, Chief Executive Officer of Fusion Connect. "We have built an exceptional team and a strong foundation based on operational excellence, outstanding customer service and a portfolio of solutions that address the evolving needs of businesses. Our focus now is to build on that foundation—accelerating growth, strengthening our partnerships and helping more customers simplify and modernize the way they connect, communicate and collaborate."

Fusion Connect's broad portfolio of products and solutions, backed by U.S.-based service and support, uniquely positions the company to meet the evolving needs of businesses as cloud communications, managed connectivity, security and AI increasingly converge. McClintock will lead Fusion Connect's strategy to capitalize on this growing market opportunity while strengthening the company's position as a trusted provider and maintaining its focus on service excellence, operational performance and long-term customer value.

About Fusion Connect

Fusion Connect is a leading provider of cloud communications and managed services, helping businesses simplify and modernize their communications and technology environments. Fusion delivers a comprehensive portfolio of solutions, including managed connectivity, UCaaS, CCaaS, SD-WAN, managed security and Microsoft Teams solutions, backed by U.S.-based service and support. The company's commitment to exceptional customer support is backed by industry-leading customer satisfaction ratings, net promoter scores for customer loyalty and service quality guarantees. To learn more, visit www.fusionconnect.com or contact an expert at +1-888-301-1721.

Media Contact: John Nee, Chief Marketing Officer

[email protected]

SOURCE Fusion Connect

Share this article